Abstract / Description of output
The National Cancer Institute of Canada Clinical Trials Group MA.17 trial examined the efficacy of letrozole (LET) started within 3 months of 5 years of adjuvant tamoxifen in postmenopausal hormone receptor-positive early-stage breast cancer. When the trial was unblinded, patients who received placebo (PLAC) were offered LET.
Original language | English |
---|---|
Pages (from-to) | 1948-55 |
Number of pages | 8 |
Journal | Journal of Clinical Oncology |
Volume | 26 |
Issue number | 12 |
DOIs | |
Publication status | Published - 2008 |
Keywords / Materials (for Non-textual outputs)
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Breast Neoplasms
- Chemotherapy, Adjuvant
- Cohort Studies
- Disease-Free Survival
- Double-Blind Method
- Drug Administration Schedule
- Female
- Humans
- Middle Aged
- Neoplasms, Hormone-Dependent
- Nitriles
- Placebos
- Postmenopause
- Tamoxifen
- Treatment Outcome
- Triazoles